The US Food and Drug Administration appears poised to continue with a plan to ban prescription fluoride supplements at a time ...

supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens. A copy of the ...

Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials. Read my analysis ...

United Bankshares, Inc. (NASDAQ: UBSI) ("United"), today reported record earnings for the second quarter of 2025 of $120.7 million, or $0.85 per diluted share. Second quarter of 2025 results produced ...

EU trade chief plans talks with US counterparts Monday Takeda ( TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, ...

Se Jin Park, a researcher from Professor Yong Man Ro’s team at KAIST, has announced 'SpeechSSM', a spoken language model capable of generating long-duration speech that sounds natural and remains ...

A rare Guillain-Barré syndrome recurrence caused nausea with no motor symptoms but was treated successfully with intravenous ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Protagonist Therapeutics, Inc.Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy ...

A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” and 1 day of acute “9 out of 10” left eye pain.She had a medical history of ...

Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...